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Abstract
Histone acetyltransferases (HATs), p300 and cAMP response element binding protein (CREB)-
binding protein (CBP) are two structurally related transcriptional co-activators that activate
expression of many eukaryotic genes involved in cellular growth and signaling, muscle
differentiation and embryogenesis. However, whether these proteins play important and different
roles in mouse cardiogenesis is not clear. Here, we investigate the protein distributions and mRNA
expression of the two HATs in embryonic and adult mouse heart during normal heart development
by using immunohistochemical and RT-PCR techniques. The data from immunohistochemical
experiments revealed that p300 was extensively present in nearly every region of the hearts from
embryonic stages to the adulthood. However, no CBP expression was detected in embryonic
hearts at day E7.5. CBP expression appeared at the later stages, and the distribution of CBP was
less than that of p300. In the developmental hearts after E10.5, both for p300 and CBP, the mRNA
expression levels reached a peak on day E10.5, and then were gradually decreased afterwards.
These results reveal that both p300 and CBP are related to embryonic heart development. The
dynamic expression patterns of these two enzymes during mouse heart development indicate that
they may play an important role on heart development. However, there is a difference in
spatiotemporal expression patterns between these two enzymes during heart development. The
expression of p300 is earlier and more predominate, suggesting that p300 may play a more
important role in embryonic heart development especially during cardiac precursor cell induction
and interventricular septum formation.
Background
The heart is the first functional organ during embryogen-
esis and its formation is initiated in a region of anterior
mesoderm known as the cardiac crescent at about embry-
onic day 7.5 (E 7.5) in mice. Soon after their specification,
the cardiac crescent from cardiac precursor cells converges
along the ventral midline of the embryos to form the lin-
ear heart tube at around day E 8.5, which undergoes loop-
ing, chamber growth, specification and ultimately four-
chamber formation [1,2].
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play a critical role in the process of cardiogenesis [3]. His-
tone acetyltransferases (HATs) and chromatin remodeling
complexes facilitate chromatin opening and promote
gene transcription [4]. The transcriptional co-activator
p300 and CBP are HATs that regulate gene expression by
acetylating histones and play central roles in a wide range
of cellular processes during heart development [5-7]. CBP
and p300 are highly homologous proteins that are well
conserved among eukaryotic cells and have been consid-
ered to be functionally equivalent [8]. However, the
reports from recent studies indicate that the two proteins
may have different distribution patterns and functions in
embryogenesis [9-14].
The role of CBP and p300 during the development was
first revealed by the observations that human CBP gene
was disrupted in a dominant genetic disorder, Rubinstein-
Taybi Syndrome (RTS), which was characterized by
craniofacial and limb defects, mental retardation as well
as developmental anomalies of the eye, heart, kidney,
lung, skin and testes [15]. In the subsequent gene disrup-
tion experiments in mice, it has been reported that mam-
malian development was tightly relevant to the CBP and
p300 since knockout of p300 in mice resulted in an
embryonic death of homozygous mutants during the days
E 9 and E11.5 manifesting the defects in neurulation, cell
proliferation, and heart development [16]. The CBP null
animals exhibit a phenotype very similar to that observed
in the p300 null mice. The homozygous mutants of CBP
died on days E10.5-E12.5 with a massive hemorrhage in
central nervous system, cranial neural tube closure defects
and a developmental retardation in both primitive and
definitive hematopoiesis. However, abnormal heart for-
mation was not observed in CBP-deficient embryos [17].
Inactivation of acetyltransferase (AT) domain of murine
p300 or CBP using a knock-in approach resulted in an
increase of embryonic or neonatal lethality in mice. In
addition, p300 AT domain mutations can cause multiple
defects in the heart, lung and intestine formation, indicat-
ing that p300 AT plays a critical role in organogenesis
[18]. p300 and CBP are generally present in mouse
oocytes and pre-implanted embryos, and they experience
the specific pattern of trafficking from the cytoplasm to
the nucleus at different stages during the growth of
oocytes [12].
Although it is well established that CBP and p300 are
involved in transcription and development, scant infor-
mation is available about the expression patterns and dis-
tributions of these two HATs in the hearts during the
development. In the present study, we have systematically
analyzed the p300 and CBP expressions during mouse
cardiogenesis using RT-PCR and immunohistochemical
techniques. The dynamic expression patterns of these two
enzymes during mouse heart development indicate that
they may play an important role on heart development.
The expression of p300 is earlier and more predominate,
suggesting that p300 may play a more important role in
embryonic heart development especially during cardiac




28–32 g KM mice were purchased from Experimental Ani-
mal Center of Chongqing Medical University. Animals
were mated at 5:00 pm and females examined for a vagi-
nal plug the following morning. The noon of the day
when a vaginal plug was confirmed was considered as
E0.5. Female mice were killed by cervical dislocation. The
whole embryos at E7.5-E9.5 were collected. The whole
hearts from embryonic mice at E10.5-E18 and from 1-
day-old neonatal mice or from adult mice were collected
accordingly. All procedures were approved by the Animal
Care and Use Committee at the Chongqing Medical Uni-
versity (Chongqing, China)
Immunohistochemical experiments
For immunohistochemical experiments, 3 embryos or 3
embryonic hearts or hearts from different mice at the
same developmental stage were used and the embryo or
heart samples were immediately fixed in fresh neutral for-
malin (37%–40% formalin, three-distilled water 880 ml,
NaH2PO4 4 g, Na2HPO4 13 g) for 3–48 hours depending
on the stage of the samples and embedded in paraffin
wax. Thereafter, the specimens were sectioned at a thick-
ness of 7 μm. Sections were deparaffinized, hydrated
through gradual ethanol steps, and briefly rinsed in water.
Endogenous peroxidases were inactivated by incubating
the slides in 3% H2O2 (30% H2O2 10 ml, methanol 90
ml) for 10 minutes. Antigens retrieval was performed by
boiling the slides in citrate buffer solution (trisodium cit-
rate 3 g, citric acid 0.4 g, 1000 ml three-distilled water, PH
6.0) for 3 times and each time was separated by an interval
duration 8 minutes. The unspecific protein binding sites
on the sections were preblocked with 10% goat serum for
10 min. Slides were incubated with primary antibodies.
CBP and p300 primary antibodies were purchased from
Abcam Inc. (Cambridge, MA). Mouse monoclonal anti-
p300 (ab3164) was diluted to 1:25 in PBS. Rabbit poly-
clonal anti-CBP (ab32646) was diluted to 1:700 in PBS.
Samples were incubated with respective antibodies for
overnight at 4°C and samples without primary antibodies
were used as controls. Slides were then incubated with
corresponding biotin-conjugated secondary antibody and
HRP-conjugated third antibody for 30 min at 37°C in a
wet box, respectively. Color reaction was generated for 3–
5 min with DAB and stopped by rinsing the slides in dis-
tilled water. Finally, the slides were re-stained with hema-Page 2 of 10
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viewed using a Leica TCS SL microscope (Leica LCS Ver-
sion 2.0).
Total RNA isolation and RT-PCR analysis
Total RNA was isolated and reverse transcribed from
pooled hearts at each stage (5–10 hearts per stage), rang-
ing from E10.5 to E18 embryos, and from neonatal day 1
(n = 3) or from adult mice (n = 1) according to a reference
previously described [19]. The extraction was performed
using an Eukaryotic Perfect RNA Extract Kit (Genemega,
China) following the manufacturer's protocols. Contami-
nating endogenous RNase was removed by treatment with
DEPC (Amresco, USA) for 8 hour at room temperature.
First-strand cDNA synthesis was carried out at 42°C for 1
hour using 6 μl of total RNA, oligo-dT primers and Super-
script RNase H-reverse transcriptase (Promega Inc, Madi-
son, WI.) according to the manufacturer's instruction.
PCR was performed using 2 μl of First-Strand reaction
mixture. As a negative control for genomic DNA contam-
ination each sample was subjected to the same reaction
without reverse transcriptase.
The specific primers were designed to detect mouse p300,








Amplification conditions for p300 were a 7 minute hot
start at 95°C followed by 35 cycles of 95°C for 1 minute,
60°C for 40 sec, and 72°C for 1 minute and a final exten-
sion at 72°C for 5 minute. The conditions for CBP were a
5 minutes hot start at 94°C followed by 35 cycles of 94°C
for 1 minute, 54°C for 30 sec, and 72°C for 30 sec and a
final extension at 72°C for 5 minutes. Conditions for β-
actin were a 5 minutes hot start at 94°C followed by 30
cycles of 95°C for 1 minute, 58°C for 40 sec, and 72°C for
40 sec and a final extension at 72°C for 5 minute. All
amplification products were resolved in a 1.5% agarose
gel and sequencing confirmed the identity of each PCR
amplified product and electrophoresis and the bands were
analyzed with a Gelatin image formation meter (Bio-Rad)
and Quantity One Version 4.4. The quantity of β-actin was
used as an internal control to normalize the relative
expression levels of p300 mRNA and CBP mRNA. Each
experiment was repeated at least three times.
Western Blotting
Nuclear proteins from fresh E10.5 embryo hearts were
extracted using the Nuclear Extract Kit (ActiveMotif, Inc,
Carlsbad, CA) according to manufacturer's instructions.
Nuclear proteins were separated and electrophoresed on
6% Bis-Tris polyacrylamide gels and then transferred to a
PDVF membrane. Blots were blocked in TBS plus 5% non-
fat milk for 1 h. Then the blots were probed with either
antibody against p300 (Abcam, ab3164, 1:200 dilution)
or CBP (Abcam, ab32646, 1:1000 dilution) at 4°C over-
night, and HRP conjugated goat anti-IgG antibody was
used as the secondary antibody. Protein bands were
revealed with an Enhanced Chemiluminescence Luminal
reagent (Santa Cruz, CA), scanned and analyzed with
Quantity One Version 4.4 software.
Statistical analysis
Data were expressed as mean ± standard deviation (SD)
and statistical differences in measured mRNA level
between various experimental groups were assessed using
an independent F-test with SAS (version 9). All tests used
a α level of 0.05.
Results
Distributions of p300 and CBP during heart development
The specificity of the antibodies was confirmed using
nuclear protein extracts of E10.5 embryo hearts by West-
ern blotting. As shown in Figure 1, both p300 (A, B) and
CBP (C, D) protein expression was detected in E10.5
embryo hearts using the antibodies described in the
"Materials and Methods".
We further analyzed the distribution of p300 and CBP
proteins using immunohistochemical techniques in
CBP and p300 are detected by Western blotting in mouse embryonic heart samplesFigure 1
CBP and p300 are detected by Western blotting in 
mouse embryonic heart samples. Representative West-
ern blots indicate that p300 and CBP were recognized by the 
specific antibodies against p300 and CBP respectively in 
nuclear protein extracts from E10.5 embryonic hearts. The 
experiments were performed as described in "Material and 
Methods" and the reaction was revealed by enhanced chemi-
luminescence assays (ECL).Page 3 of 10
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(E7.5) to the adult stages.
We showed that during the early embryonic heart devel-
opment stages (E7.5-E9.5), p300 was highly expressed in
crescent-shaped cardiogenic plate (future myocardium) at
E7.5 (Figure 2A), while no CBP expression was detected in
this region at the same stage (Figure 2D). We also showed
that p300 was highly expressed at E8.5 in the fusing heart
tubes including endocardium primordium and myoepi-
cardial mantle, the presumptive regions of myocardium
and epicardium (Figure 2B). Similarly, we found high
level expression of p300 at E9.5 in the looping heart tubes
which include all cardiac compartments, i.e. primary
atrial and ventricular myocardium as well as outflow tract
(Figure 2C). CBP was also observed in these regions at
E8.5 and E9.5, however, the protein level was much less
compared to p300 (Figures 2E & 2F).
During the chamber specific forming and septation
stages(E10.5-E15.5), the mouse heart morphological
changes were observed as follows. The mouse heart was
unseptated at E9.5, and looped tube formed which had
three oncoideses, i.e. bulbus cordis, primary ventricle and
primary atria from top to end. As heart developed further,
confined atrioventricular canal (AVC) formed between
atria and ventricle. Meanwhile, the endocardial cushions
(EC) became visible at E10.5 in the AVC. At this stage,
ventricular trabeculae were evidently visible within the
presumptive right ventricle (RV) and left ventricle (LV). By
E11.5, there had been evidently visible EC and gradually
forming primary atrial septum (PAS) as well as considera-
ble growth of the muscular interventricular septum (IVS)
so that the RV and LV were now separated apically, which,
at this stage, the ridges within the outflow tract (OFT) had
started to appear and face to fuse, and the mesenchymal
swellings that would become the atrioventricular valves
were visible. By E13.5, second atrial septum had com-
pletely formed, and aortico-pulmonary septum had
formed so that the pulmonary artery and ascending aorta
were separated. Meanwhile, atrial trabeculae were visible.
By E14.5, membranous IVS resourced from EC had fused
to muscular IVS. By E15.5, tricuspid and mitral valves had
formed at the right and left atrioventricular foramen,
respectively. As shown in Figure 3, in these stages, p300
was highly expressed in developing chamber walls, i.e.
ventricular myocardium, atrial myocardium and interatria
septum (IAS), IVS, trabeculae, atrioventricular EC and
OFT which gradually developed into pulmonary artery
and ascending artery (Figures 3A–I). However, CBP distri-
bution was not so even as we found a higher distribution
in atrioventricular myocardium and a relatively lower dis-
tribution in atrioventricular valves, trabeculae and OFT
and a very low distribution in the developing muscular
IVS and membranous IVS (Figures 3J–R).
At late fetal developmental stages (from E16.5 till born),
the heart has complete four chambers separated by IAS,
IVS and the atrioventricular valves. As the heart devel-
oped, the myocardial cell number increases, which
resulted in a bigger heart. In embryonic hearts (E16.5 and
E18), we found that p300 was highly expressed in myo-
cardium and trabeculae, but relatively lowly expressed in
septum and valves (Figures 4A & 4B). We also showed that
CBP expressions were relatively low in myocardium and
trabeculae, as well as in muscular IVS and lower expres-
sions in membranous IVS (Figures 4G & 4F). Similar find-
ings were observed in the postnatal day 1 hearts (Figures
4C, D, H, I).
In adult mouse hearts, relatively high expressions of p300
were observed in chamber walls (Figure 4E) and low
expressions of p300 were found in septum and valves
(data not shown). However, low expressions of CBP were
observed in chamber walls (Figure 4J) and muscular IVS.
CBP in membranous IVS was extremely low (data not
shown).
p300 and CBP mRNA expressions during mouse heart 
development
We further investigated p300 and CBP mRNA expression
levels during mouse cardiogenesis using RT-PCR tech-
niques. This enabled a comparison of the semi-quantita-
tive expression of p300 and CBP mRNA level at different
developmental stages to be made. These data were
expressed as a ratio of p300 or CBP to β-actin expression
levels. The earliest time of collecting cardiac tissues for RT-
PCR was day E10.5 which was the earliest stage to gain the
completely isolated heart. The expression levels of both
p300 and CBP gradually diminished after day E12.5 but a
weak expression was still observed on day 1 after birth and
in adult hearts (Figure 5). The mRNA expression data are
consistent with the results we obtained from the immuno-
histochemical studies.
Discussion
The current model of mammalian heart development
indicates that the crescent primary heart primordium
derived first from cardiac precursor cells (on day E7.5 in
mice) undergoes fusion to form primary linear heart tube
(on day E8.5). Then the tube loops to form primary cham-
ber (E9.5). The chamber separation occurs on E10.5 –
E15.5 to ultimately form a four-chambered heart and the
heart continue to grow till the consummation. During the
process, cardiac cell differentiation plays a critical role to
allow certain genes to be expressed at a given stage of the
development [20]. The selection applies to either the acti-
vation or the repression of certain cardiac genes. Modifi-
cation of histone acetylation by HATs is an important
pattern to control the gene expressions. Both p300 and
CBP are the members of the HATs family and they are aPage 4 of 10
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Protein expression patterns of p300 and CBP in early embryonic heartsFigure 2
Protein expression patterns of p300 and CBP in early embryonic hearts. Lateral view of E7.5 embryo shows a high 
expression of p300 in cardiac crescents (arrow) at the anterior of the embryo (A). No expression of CBP was detected in car-
diac crescents of a E7.5 embryo (arrow)(B). Lateral view of E8.5 embryo shows a high expression of p300 in linear heart tube 
at midline of the embryo including endocardium primordium (arrow) and myoepicardial mantle (arrowhead) which are the pre-
sumptive regions of myocardium and epicardium (C). Lateral view of E8.5 embryo shows a relatively low expression of CBP in 
the endocardium primordium (arrow) and myoepicardial mantle (arrowhead)(D). Lateral view of E9.5 embryo shows a high 
expression of p300 in looping heart tube at the left of the embryo including endocardium primordium (arrow) and myoepicar-
dial mantle (arrowhead)(E). Lateral view of E9.5 embryo shows a relatively low expression of CBP in the looping heart tube 
including endocardium primordium (arrow) and myoepicardial mantle (arrowhead). Magnification: ×200.
Journal of Biomedical Science 2009, 16:24 http://www.jbiomedsci.com/content/16/1/24Figure 3 (see legend on next page)Page 6 of 10
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referred to as a single entity [21]. Although it has been
reported that p300 and CBP are essential for multi-orga-
nogenesis [8-14], little is known about their locations and
dynamic expression in the heart during the development.
In this study, we have investigated the distributions of
these two enzymes in the heart during the heart formation
from the very beginning of the cardiac crescent forming at
E7.5 to adult heart using immunohistochemistry and RT-
PCR to better understand the roles of these two enzymes
on cardiogenesis. Our RT-PCR data have shown that both
CBP and p300 are present in the heart during the develop-
ment from E10.5 till adulthood with a similar dynamic
variance and a high expression at the early stages of cham-
ber septation. In addition, we have observed that p300 is
highly expressed in the heart from E10.5 to E11.5 with a
peak expression at E10.5 whereas CBP is highly expressed
from E10.5 to E12.5 and with a peak expression at the
same time. Expression of both p300 and CBP is gradually
decreased in the subsequent heart development stages till
the postnatal and adulthood stages, suggesting that p300
and CBP are required for gene expression during the heart
development. Furthermore the findings also support the
notion that both enzymes have a concomitant transcrip-
tional regulation during cardiogenesis.
However the immunohistochemical data reveal different
distribution patterns of p300 and CBP in early stages of
heart development, suggesting a potential functional dif-
ference between these two enzymes. In the stage of cardiac
precursor cells induction (day E7.5), p300 has a much
higher distribution than CBP in crescent-shaped cardio-
genic plate, indicating that p300 probably plays a more
important role on cardiac progenitor cells induction and
migration. p300 is highly distributed in all areas of heart
including cardiac walls, septum, trabeculae, developing
cardiac cushions and valves during the subsequent stages
from the fetal development till the postnatal day 1. In
adult mouse hearts, a relatively high presentation of p300
is observed in the walls and a lower distribution is seen in
the septum and the valves. Unlike p300, CBP has a differ-
ent distribution pattern. A relatively high presentation of
CBP is found in the early linear cardiac tube at E8.5 and in
the looping cardiac tube at E9.5. From the chamber septa-
tion and late heart development stages till the postnatal
day 1. CBP is found with a high concentration in atrioven-
tricular walls and with a less content in atrioventricular
valves, trabeculae, and a very low level in developing mus-
cular IVS and a lower expression in forming membranous
IVS. In adult mouse hearts, a low level of CBP is observed
in walls and muscular IVS and extremely low content of
CBP is observed in membranous IVS. These findings sug-
gest that both p300 and CBP may participate in the mor-
phogenesis of heart, which is in consistent with the results
from the RT-PCR experiments in this study. However
p300 may have more important functions than CBP for
heart development, since it has a broader distribution in
the heart especially during the stages of trabeculation and
cardiac septum formation. These observations are consist-
ent with the previous studies [22,23].
In general, the expression of p300 and CBP is ubiquitous
in mammalians [9,16]. The phenotypes observed in trans-
genic mice harboring mutated CBP or p300 indicate that
both CBP and p300 are essential for normal embryogene-
sis [16]. Our experimental results suggest that p300 is
ubiquitously expressed in developing hearts and through-
out postnatal as well as in adult hearts. The distribution
pattern of p300 in the heart during development is similar
to that of CBP with an expectation that no CBP is found
on day E7.5.
Although p300 and CBP have great similarity in both bio-
chemical structures and functions, increasing researches
have shown that CBP and p300 might possess distinct
developmental functions due to differences in their distri-
bution and expression patterns. Animals with deficiency
of p300 or CBP exhibited abnormal phenotypes suggest-
ing that CBP and p300 cannot be replaced in the
homozygous mutant mice [16,17]. It is known that
patients suffering from Rubinstein-Taybi syndrome, an
autosomal dominant syndrome characterized by abnor-
mal growth and mental retardation as well as abnormal
heart development, commonly have CBP gene mutations
Expressions of p300 and CBP in embryonic hearts during chamber formation and septation stages from E10.5 to E15.5Figure 3 ( ee previous page)
Expressions of p300 and CBP in embryonic hearts during chamber formation and septation stages from E10.5 
to E15.5. E10.5 embryo heart shows a high p300 expression (A) and a relative low expression of CBP (B) in most cardiac 
compartments, in particular in the trabeculae (arrow) and ventricular myocardium (arrowhead). C shows a high expression of 
p300 at E11.5 in atria and ventricle walls (arrowhead), ventricular trabeculae (arrow). D shows that a high expression of CBP 
was found at E11.5 in atrioventricular myocardium (arrowhead), a relatively low expression of CBP was found in trabeculae 
(arrow) and OFT. At E12.5, p300 is highly expressed in atria and ventricle walls (arrowhead), ventricular trabeculae (arrow)(E). 
A similar CBP expression pattern is shown in E12.5 embryos (F) in cardiac walls (arrowhead) and trabeculae (arrow). In E14.5 
embryonic heart, p300 is highly and extensively expressed in walls, ventricular trabeculae, muscular IVS and nascent membra-
nous IVS, nascent pulmonary artery and aorta (G). At the same stage, CBP is highly expressed in atrioventricular myocardium 
and lowly expressed in atrioventricular valves, trabeculae and OFT (H).Page 7 of 10
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p300 and CBP expressions in mouse hearts at late fetal stages, postnatal day 1 and adulthood stagesFigure 4
p300 and CBP expressions in mouse hearts at late fetal stages, postnatal day 1 and adulthood stages. p300 is 
highly expressed in myocardium (arrowhead) and trabeculae (arrow) but relatively lowly expressed in septum and valves in E18 
embryonic heart (A) and in postnatal day 1 heart (C). A relatively low expression of CBP in myocardium (arrowhead) and 
trabeculae (arrow) was shown in E18 embryonic heart (B) and postnatal day 1 heart (D). In adult mouse hearts, both p300 (E) 
and CBP (F) expression were low.
Journal of Biomedical Science 2009, 16:24 http://www.jbiomedsci.com/content/16/1/24(resulting in lower CBP levels) while the p300 gene of
these patients is considered to be normal [15,24,25]. In F9
cells, retinoic acid induced differentiation is dependent
on p300 but not on CBP [26]. CBP is found to be localized
mainly within the oocyte nucleus while p300 is localized
in the cytoplasm after two-cell stage and they could not
replace each other in these processes [12]. Moreover, a full
complement of CBP, but not p300, is required for normal
hematopoietic differentiation [27,28]. In consistent with
all these reports, our results indicate that there are differ-
ences between p300 and CBP in both distribution and
temporal expression pattern during the heart develop-
ment.
Conclusion
Our data show that the expression of CBP and p300 is
developmentally regulated during mouse cardiogenesis.
There are differences between CBP and p300 in both tis-
sue distributions and mRNA expression levels during
heart development. These observations shed new light on
the function of CBP and p300 during heart development
and provide us with a molecular basis for further under-
standing the mechanisms underlying cardiogenesis and
some congenital heart diseases.
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